Voltage-Gated Sodium Channels: Structure, Function, Pharmacology, and Clinical Indications

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7093-7118

  De Lera Ruiz, Manuel ^a   Kraus, Richard L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 3161; BATRACHOTOXIN; BREVETOXIN; CIGUATOXIN; CNV 1014802; CONOTOXIN; DSP 2230; ELECLAZINE; GS 6614; GSK 2339345; NATURAL PRODUCT; NKTR 171; PF 04531083; SCORPION VENOM; SODIUM CHANNEL BLOCKING AGENT; SPIDER VENOM; UNCLASSIFIED DRUG; VERATRIDINE; VOLTAGE GATED SODIUM CHANNEL; XEN 402; BIOLOGICAL PRODUCT; LIGAND; PROTEIN SUBUNIT; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; HUMAN; LIGAND BINDING; NOCICEPTION; NONHUMAN; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SUBUNIT; REVIEW; ANIMAL; CARDIOVASCULAR DISEASES; CHANNEL GATING; CHANNELOPATHIES; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; EPILEPSY; GENETICS; METABOLISM; MUTATION; NEOPLASMS; NEUROMUSCULAR DISEASES; PAIN; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; RESPIRATORY TRACT DISEASES;

ANIMALS; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; CHANNELOPATHIES; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; EPILEPSY; HUMANS; ION CHANNEL GATING; LIGANDS; MUTATION; NEOPLASMS; NEUROMUSCULAR DISEASES; PAIN; PROTEIN STRUCTURE, TERTIARY; PROTEIN SUBUNITS; RESPIRATORY TRACT DISEASES; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84942284225     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501981g     Document Type: Review

References (226)

1. Peters, C. H.; Ruben, P. C.; Groome, J. R.; Silva, J.; Calhoun, J. D.; Isom, L. L.; Lampert, A.; Eberhardt, M.; Waxman, S. G.; Chahine, M.; OLeary, M. E.; Antzelevitch, C.; Nesterenko, V.; Shryock, J. C.; Rajamani, S.; Song, Y.; Belardinelli, L.; Jones, D. K.; Goldschen-Ohm, M. P.; Chanda, B.; Gilchrist, J.; Olivera, B. M.; Bosmans, F.; Laedermann, C. J.; Decosterd, I.; Abriel, H.; Corry, B.; Lee, S.; Ahern, C. A.; Scheuer, T. Voltage gated sodium channels Handb. Exp. Pharmacol. 2014, 221, 1-295
2. Nardi, A.; Damann, N.; Hertrampf, T.; Kless, A. Advances in targeting voltage-gated sodium channels with small molecules ChemMedChem 2012, 7, 1-30
3. Hodgkin, A. L.; Huxley, A. F. A quantitative description of membrane current and its application to conduction and excitation in nerve J. Physiol. 1952, 117 (4) 500-544
4. Agnew, W. S.; Levinson, S. R.; Brabson, J. S.; Raftery, M. A. Purification of the tetrodotoxin-binding component associated with the voltage-sensitive sodium channel from Electrophorus electricus electroplax membrane Proc. Natl. Acad. Sci. U. S. A. 1978, 75, 2606-2610
5. v2/NaG channel is involved in control salt-intake behavior in the CNS J. Neurosci. 2000, 20 (20) 7743-7751
6. Catterall, W. A.; Goldin, A. L.; Waxman, S. G. International Union of Pharmacology. XLVII. Nomenclature and structure-function relationships of voltage-gated sodium channels Pharmacol. Rev. 2005, 57 (4) 397-409
7. Goldin, A. L. Diversity of mammalian voltage-gated sodium channels Ann. N. Y. Acad. Sci. 1999, 868, 38-50
8. Cestèle, S.; Catterall, W. A. Molecular mechanisms of neurotoxin action on voltage-gated sodium channels Biochimie 2000, 82 (9-10) 883-892
9. Based on SciFinder searches using "sodium channel" and "SCN9A", December 18, 2014.
10. Beneski, D. A.; Catterall, W. A. Covalent labeling of protein components of the sodium channel with a photoactivable derivative of a scorpion toxin Proc. Natl. Acad. Sci. U. S. A. 1980, 77, 639-643
11. Hartshorne, R. P.; Catterall, W. A. Purification of the saxitoxin receptor of the sodium channel from rat brain Proc. Natl. Acad. Sci. U. S. A. 1981, 78, 4620-4624
12. Hartshorne, R. P.; Messner, D. J.; Coppersmith, J. C.; Catterall, W. A. The saxitoxin receptor of the sodium channel from rat brain. Evidence for two nonidentical β subunits J. Biol. Chem. 1982, 257, 13888-13891
13. Payandeh, J.; Scheuer, T.; Zheng, N.; Catterall, W. A. The crystal structure of a voltage-gated sodium channel Nature 2011, 475 (7356) 353-358
14. Payandeh, J.; Gamal, T. M.; Scheuer, T.; Zheng, N.; Catterall, W. A. Crystal structure of a voltage-gated sodium channel in two potentially inactivated states Nature 2012, 486 (7401) 135-139
15. Zhang, X.; Ren, W.; DeCaen, P.; Yan, C.; Tao, X.; Tang, L.; Wang, J.; Hasegawa, K.; Kumasaka, T.; He, J.; Wang, J.; Clapham, D. E.; Yan, N. Crystal structure of an orthologue of the NaChBac voltage-gated sodium channel Nature 2012, 486 (7401) 130-134
16. McCusker, E. C.; Bagnéris, C.; Naylor, C. E.; Cole, A. R.; DAvanzo, N.; Nichols, C. G.; Wallace, B. A. Structure of a bacterial voltage-gated sodium channel pore reveals mechanisms of opening and closing Nature Commun. 2012, 3, 1102
17. Catterall, W. A. Structure and function of voltage-gated sodium channels at atomic resolution Exp. Physiol. 2014, 99 (1) 35-51
18. vMs channel as a structural and functional model for eukaryotic sodium channel antagonism Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (23) 8428-8433
19. Ullmschneider, M. B.; Bagnéris, C.; McCusker, E. C.; DeCaen, P. G.; Delling, M.; Clapham, D. E.; Ulmschneider, J. P.; Wallace, B. A. Molecular dynamics of ion transport through the open conformation of a bacterial voltage-gated sodium channel Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (16) 6364-6369
20. Tsai, C.-J.; Tani, K.; Irie, K.; Hiroaki, Y.; Shimomura, T.; McMillan, D. G.; Cook, G. M.; Schertler, G. F. X.; Fujiyoshi, Y.; Li, X.-D. Two alternative conformations of a voltage-gated sodium channel J. Mol. Biol. 2013, 425, 4074-4088
21. Boiteus, C.; Vorobyov, I.; Allen, T. W. Ion conduction and conformational flexibility of a bacterial voltage-gated sodium channel Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (9) 3454-3459
22. Finol-Urdaneta, R. K.; Wang, Y.; Al-Sabi, A.; Zhao, C.; Noskov, S. Y.; French, R. J. Sodium channel selectivity and conduction: prokaryotes have devised their own molecular strategy J. Gen. Physiol. 2014, 143 (2) 157-171
23. Bagnéris, C.; DeCaen, P. G.; Hall, B. A.; Naylor, C. E.; Clapham, D. E.; Kay, C. W. M.; Wallace, B. A. Role of the C-terminal domain in the structure and function of tetrameric sodium channels Nature Commun. 2013, 4, 3465-3473
24. Pless, S. A.; Elstone, F. D.; Niciforovic, A. P.; Galpin, J. D.; Yang, R.; Kurata, H. T.; Ahern, C. A. Asymmetric functional contributions of acidic and aromatic side chains in sodium channel voltage-sensor domains J. Gen. Physiol. 2014, 143 (5) 645-656
25. Kaczmarski, J. A.; Corry, B. Investigating the size and dynamics of voltage-gated sodium channel fenestrations Channels 2014, 8 (3) 264-277
26. v) protein dissection creates a set of functional pore-only proteins Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 12313-12318
27. Shaya, D.; Findeisen, F.; Abderemane-Ali, F.; Arrigoni, C.; Wong, S.; Nurva, S. R.; Loussouarn, G.; Minor, D. L., Jr. Structure of a prokaryotic sodium channel pore reveals essential gating elements and an outer ion binding site common to eukaryotic channels J. Mol. Biol. 2014, 426, 467-483
28. Heinemann, S. H.; Terlau, H.; Stühmer, W.; Imoto, K.; Numa, S. Calcium channel characteristics conferred on the sodium channel by single mutations Nature 1992, 356, 441-443
29. + selectivity in mammalian voltage-gated sodium channels based on molecular dynamics simulation Biophys. J. 2013, 104, 2401-2409
30. vRh Cell Res. 2013, 23, 409-422
31. Catterall, W. A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels Neuron 2000, 26, 13-25
32. Yang, Y.; Estacion, M.; Dib-Hajj, S. D.; Waxman, S. G. Molecular architecture of a sodium channel S6 helix J. Biol. Chem. 2013, 288 (19) 13741-13747
33. v1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability Brain 2011, 134, 1972-1986
34. Oelstrom, K.; Goldschen-Ohm, M. P.; Holmgren, M.; Chanda, B. Evolutionarily conserved intracellular gate of voltage-dependent sodium channels Nature Commun. 2014, 5, 3420
35. Jones, D. K.; Peters, C. H.; Allard, C. R.; Claydon, T. W.; Ruben, P. C. Proton sensors in the pore domain of the cardiac voltage-gated sodium channel J. Biol. Chem. 2013, 288 (7) 4782-4791
36. + channel β subunits: overachievers of the ion channel family Front. Pharmacol. 2011, 2, 53
37. v channel β3 subunit indicates a trimeric assembly J. Biol. Chem. 2014, 289 (15) 10797-10811
38. +-mediated activity of voltage-gated sodium channels in primary cortical neurons Biochem. J. 2014, 457, 27-31
39. Shavkunov, A. S.; Wildburger, N. C.; Nenov, M. N.; James, T. F.; Buzhdygan, T. P.; Panova-Elektronova, N. I.; Green, T. A.; Veselenak, R. L.; Bourne, N.; Laezza, F. The fibroblast growth factor 14-voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3) J. Biol. Chem. 2013, 288 (27) 19370-19385
40. vβ4 open-channel blocking peptide J. Gen. Physiol. 2013, 142 (3) 191-206
41. Eijkelkamp, N.; Linley, J. E.; Baker, M. D.; Minett, M. S.; Cregg, R.; Werdehausen, R.; Rugiero, F.; Wood, J. N. Neurological perspectives on voltage-gated sodium channels Brain 2012, 135, 2585-2612
42. Lampert, A.; Eberhardt, M.; Waxman, S. G. Altered sodium channel gating as molecular basis for pain: contribution of activation, inactivation, and resurgent currents Handb. Exp. Pharmacol. 2014, 221, 91-110
43. Jarecki, B. W.; Piekarz, A. D.; Jackson, J. O.; Cummins, T. R. Human voltage-gated sodium channel mutations that cause inherited neuronal and muscle channelopathies increase resurgent sodium currents J. Clin. Invest. 2010, 120 (1) 369-378
44. Tan, Z. Y.; Piekarz, A. D.; Priest, B. T.; Knopp, K. L.; Krajewski, J. L.; McDermott, J. S.; Nisenbaum, E. S.; Cummins, T. R. Tetrodotoxin-resistant sodium channels in sensory neurons generate slow resurgent currents that are enhanced by inflammatory mediators J. Neurosci. 2014, 34 (21) 7190-7197
45. Jurkat-Rott, K.; Groome, J.; Lehmann-Horn, F. Pathophysiological role of omega pore current in channelopathies Front. Pharmacol. 2012, 11, 3-112
46. Moreau, A.; Gosselin-Badaroudine, P.; Chahine, M. Biophysics, pathophysiology, and pharmacology of ion channel gating pores Front. Pharmacol. 2014, 3, 5-53
47. Black, J. A.; Waxman, S. G. Noncanonical roles of voltage-gated sodium channels Neuron 2013, 80 (2) 280-291
48. Jurkat-Rott, K.; Holzherr, B.; Fauler, M.; Lehmann-Horn, F. Sodium channelopathies of skeletal muscle result from gain or loss of function Pflugers Arch. 2010, 460 (2) 239-248
49. Sanders, S. J.; Murtha, M. T.; Gupta, A. R.; Murdoch, J. D.; Raubeson, M. J.; Willsey, A. J.; Ercan-Sencicek, A. G.; DiLullo, N. M.; Parikshak, N. N.; Stein, J. L.; Walker, M. F.; Ober, G. T.; Teran, N. A.; Song, Y.; El-Fishawy, P.; Murtha, R. C.; Choi, M.; Overton, J. D.; Bjornson, R. D.; Carriero, N. J.; Meyer, K. A.; Bilguvar, K.; Mane, S. M.; Sestan, N.; Lifton, R. P.; Günel, M.; Roeder, K.; Geschwind, D. H.; Devlin, B.; State, M. W. De novo mutations revealed by whole-exome sequencing are strongly associated with autism Nature 2012, 485 (7397) 237-241
50. Carr, M. J. Regulation of cough and action potentials by voltage-gated Na channels Pulm. Pharmacol. Ther. 2013, 26 (5) 508-509
51. Djamgoz, M. B.; Onkal, R. Persistent current blockers of voltage-gated sodium channels: a clinical opportunity for controlling metastatic disease Recent Pat. Anti-Cancer Drug Discovery 2013, 8 (1) 66-84
52. Schmunk, G.; Gargus, J. J. Channelopathy pathogenesis in autism spectrum disorders Front. Genet. 2013, 4, 222
53. Tavassoli, T.; Kolevzon, A.; Wang, A. T.; Curchack-Lichtin, J.; Halpern, D.; Schwartz, L.; Soffes, S.; Bush, L.; Grodberg, D.; Cai, G.; Buxbaum, J. D. De novo SCN2A splice site mutation in a boy with autism spectrum disorder BMC Med. Genet. 2014, 15, 35
54. v1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (43) 17546-17551
55. Catterall, W. A. Sodium channels, inherited epilepsy, and antiepileptic drugs Annu. Rev. Pharmacol. Toxicol. 2014, 54, 317-338
56. Hoeijmakers, J. G.; Faber, C. G.; Merkies, I. S.; Waxman, S. G. Channelopathies, painful neuropathy, and diabetes: which way does the causal arrow point? Trends Mol. Med. 2014, 20, 544-550 10.1016/j.molmed.2014.06.003
57. Dhalla, A. K.; Yang, M.; Ning, Y.; Kahlig, K. M.; Krause, M.; Rajamani, S.; Belardinelli, L. Diabetes 2014, 63, 3545-3556
58. v1.7 sodium channel: from molecule to man Nature Rev. Neurosci. 2013, 14 (1) 49-62
59. Bennett, D. L.; Woods, C. G. Painful and painless channelopathies Lancet Neurol. 2014, 13 (6) 587-599
60. v1.7 variant I228M impairs integrity of dorsal root ganglion neuron axons Ann. Neurol. 2013, 73 (1) 140-145
61. v1.7 mutation Pain 2014, 155, 1702-1707 10.1016/j.pain.2014.05.006
62. Cox, J. J.; Reimann, F.; Nicholas, A. K.; Thornton, G.; Roberts, E.; Springell, K.; Karbani, G.; Jafri, H.; Mannan, J.; Raashid, Y.; Al-Gazali, L.; Hamamy, H.; Valente, E. M.; Gorman, S.; Williams, R.; McHale, D. P.; Wood, J. N.; Gribble, F. M.; Woods, C. G. An SCN9A channelopathy causes congenital inability to experience pain Nature 2006, 444 (7121) 894-898
63. Cox, J. J.; Sheynin, J.; Shorer, Z.; Reimann, F.; Nicholasm, A. K.; Zubovic, L.; Baralle, M.; Wraige, E.; Manor, E.; Levy, J.; Woods, C. G.; Parvari, R. Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations Hum. Mutat. 2010, 31 (9) E1670-E1686
64. v1.7 (PN1) in acute and inflammatory pain Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (34) 12706-12711
65. v1.7 is the predominant sodium channel in rodent olfactory sensory neurons Mol. Pain 2011, 10, 7-32
66. v1.7 cause anosmia Nature 2011, 472 (7342) 186-190
67. v1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain PLoS One 2014, 9, e105895 10.1371/journal.pone.0105895
68. v1.7-dependent pain sensations require different sets of sensory and sympathetic neurons Nature Commun. 2012, 3, 791
69. Smith, E. S.; Omerbašić, D.; Lechner, S. G.; Anirudhan, G.; Lapatsina, L.; Lewin, G. R. The molecular basis of acid insensitivity in the African naked mole-rat Science 2011, 334 (6062) 1557-1560
70. v1.8 mutations in painful neuropathy Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (47) 19444-19449
71. Akopian, A. N.; Souslova, V.; England, S.; Okuse, K.; Ogata, N.; Ure, J.; Smith, A.; Kerr, B. J.; McMahon, S. B.; Boyce, S.; Hill, R.; Stanfa, L. C.; Dickenson, A. H.; Wood, J. N. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways Nature Neurosci. 1999, 2 (6) 541-548
72. v1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats Neuroscience 2007, 146 (2) 812-821
73. v1.8 facilitates nociceptive neuron firing and causes hyperalgesia in diabetic neuropathy Nature Med. 2012, 18 (6) 926-933
74. Rowe, A. H.; Xiao, Y.; Rowe, M. P.; Cummins, T. R.; Zakon, H. H. Voltage-gated sodium channel in grasshopper mice defends against bark scorpion toxin Science 2013, 342 (6157) 441-446
75. Leipold, E.; Liebmann, L.; Korenke, G. C.; Heinrich, T.; Giesselmann, S.; Baets, J.; Ebbinghaus, M.; Goral, R. O.; Stödberg, T.; Hennings, J. C.; Bergmann, M.; Altmüller, J.; Thiele, H.; Wetzel, A.; Nürnberg, P.; Timmerman, V.; De Jonghe, P.; Blum, R.; Schaible, H. G.; Weis, J.; Heinemann, S. H.; Hübner, C. A.; Kurth, I. A de novo gain-of-function mutation in SCN11A causes loss of pain perception Nature Genet. 2013, 45 (11) 1399-1404
76. v1.9 in painful neuropathy Brain 2014, 137, 1627-1642
77. Zhang, X. Y.; Wen, J.; Yang, W.; Wang, C.; Gao, L.; Zheng, L. H.; Wang, T.; Ran, K.; Li, Y.; Li, X.; Xu, M.; Luo, J.; Feng, S.; Ma, X.; Ma, H.; Chai, Z.; Zhou, Z.; Yao, J.; Zhang, X.; Liu, J. Y. Gain-of-function mutations in SCN11A cause familial episodic pain Am. J. Hum. Genet. 2013, 93 (5) 957-966
78. v1.3 and functional involvement in neuronal hyperexcitability associated with central neuropathic pain after spinal cord injury J. Neurosci. 2003, 23 (26) 8881-8892
79. v1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker Pain 2012, 153 (1) 80-85
80. Goldberg, Y. P.; Cohen, C. J.; Namdari, R.; Price, N.; Cadieux, J. A.; Young, C.; Sherrington, R.; Pimstone, S. N. Letter to the editor Pain 2014, 155 (4) 837-838
81. McCormack, K.; Santos, S.; Chapman, M. L.; Krafte, D. S.; Marron, B. E.; West, C. W.; Krambis, M. J.; Antonio, B. M.; Zellmer, S. G.; Printzenhoff, D.; Padilla, K. M.; Lin, Z.; Wagoner, P. K.; Swain, N. A.; Stupple, P. A.; de Groot, M.; Butt, R. P.; Castle, N. A. Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (29) E2724-E2732
82. Catterall, W. A. Ion channel voltage sensors: structure, function, and pathophysiology Neuron 2010, 67 (6) 915-928
83. Middleton, R. E.; Warren, V. A.; Kraus, R. L.; Hwang, J. C.; Liu, C. J.; Dai, G.; Brochu, R. M.; Kohler, M. G.; Gao, Y. D.; Garsky, V. M.; Bogusky, M. J.; Mehl, J. T.; Cohen, C. J.; Smith, M. M. Two tarantula peptides inhibit activation of multiple sodium channels Biochemistry 2002, 41 (50) 14734-14747
84. Sokolov, S.; Kraus, R. L.; Scheuer, T.; Catterall, W. A. Inhibition of sodium channel gating by trapping the domain II voltage sensor with protoxin II Mol. Pharmacol. 2008, 73 (3) 1020-1028
85. v1.7 inhibitor from centipede venom with analgesic efficacy exceeding morphine in rodent pain models Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (43) 17534-17539
86. v1.7 channel voltage sensor for pain and itch relief Cell 2014, 157 (6) 1393-1404
87. v1.9 variant p.L811P Eur. J. Hum. Genet. 2014, 23, 561-563 10.1038/ejhg.2014.166
88. v1.9 are expressed in the retina J. Comp. Neurol. 2008, 508 (6) 940-951
89. Errington, A. C.; Stöhr, T.; Heers, C.; Lees, G. The investigational anticonvulsant lacosamide selectively enhances slow inactivation of voltage-gated sodium channels Mol. Pharmacol. 2008, 73 (1) 157-169
90. Wang, G. K.; Wang, S. Y. Block of human cardiac sodium channels by lacosamide: evidence for slow drug binding along the activation pathway Mol. Pharmacol. 2014, 85 (5) 692-702
91. Sokolov, S.; Scheuer, T.; Catterall, W. A. Gating pore current in an inherited ion channelopathy Nature 2007, 446 (7131) 76-78
92. Antzelevitch, C.; Nesterenko, V.; Shryock, J. C.; Rajamani, S.; Song, Y.; Belardinelli, L. The role of late I Na in development of cardiac arrhythmias Handb. Exp. Pharmacol. 2014, 221, 137-168
93. van den Boogaard, M.; Smemo, S.; Burnicka-Turek, O.; Arnolds, D. E.; van de Werken, H. J.; Klous, P.; McKean, D.; Muehlschlegel, J. D.; Moosmann, J.; Toka, O.; Yang, X. H.; Koopmann, T. T.; Adriaens, M. E.; Bezzina, C. R.; de Laat, W.; Seidman, C.; Seidman, J. G.; Christoffels, V. M.; Nobrega, M. A.; Barnett, P.; Moskowitz, I. P. A common genetic variant within SCN10A modulates cardiac SCN5A expression J. Clin. Invest. 2014, 124 (4) 1844-1852
94. Hu, D.; Barajas-Martínez, H.; Pfeiffer, R.; Dezi, F.; Pfeiffer, J.; Buch, T.; Betzenhauser, M. J.; Belardinelli, L.; Kahlig, K. M.; Rajamani, S.; DeAntonio, H. J.; Myerburg, R. J.; Ito, H.; Deshmukh, P.; Marieb, M.; Nam, G. B.; Bhatia, A.; Hasdemir, C.; Haïssaguerre, M.; Veltmann, C.; Schimpf, R.; Borggrefe, M.; Viskin, S.; Antzelevitch, C. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome J. Am. Coll. Cardiol. 2014, 64 (1) 66-79
95. v1.7 shRNA silencing in guinea pig nodose ganglia Am. J. Physiol.: Regul. Integr. Comp. Physiol. 2013, 304 (11) R1017-1023
96. v1.9 for treatment of pathological cough Lung 2014, 192 (1) 15-20
97. Cheng, K. K.; Ling, Y. L.; Wang, J. C. The failure of respiration in death by tetrodotoxin poisoning Exp. Physiol. Cognit. Med. Sci. 1968, 53 (2) 119-128
98. Brackenbury, W. J. Voltage-gated sodium channels and metastatic disease Channels (Austin) 2012, 6 (5) 352-361
99. Frede, J.; Fraser, S. P.; Oskay-Özcelik, G.; Hong, Y.; Ioana-Braicu, E.; Sehouli, J.; Gabra, H.; Djamgoz, M. B. Ovarian cancer: ion channel and aquaporin expression as novel targets of clinical potential Eur. J. Cancer 2013, 49 (10) 2331-2344
100. Shan, B.; Dong, M.; Tang, H.; Wang, N.; Zhang, J.; Yan, C.; Jiao, X.; Zhang, H.; Wang, C. Voltage-gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells Oncol. Lett. 2014, 8 (1) 345-350
101. Nelson, M.; Millican-Slater, R.; Forrest, L. C.; Brackenbury, W. J. The sodium channel β1 subunit mediates outgrowth of neurite-like processes on breast cancer cells and promotes tumor growth and metastasis Int. J. Cancer 2014, 135 (10) 2338-2351
102. Fraser, S. P.; Ozerlat-Gunduz, I.; Brackenbury, W. J.; Fitzgerald, E. M.; Campbell, T. M.; Coombes, R. C.; Djamgoz, M. B. Regulation of voltage-gated sodium channel expression in cancer: hormones, growth factors and auto-regulation Philos. Trans. R. Soc., B 2014, 369 (1638) 20130105
103. v1.5 sodium channels to reduce migration and invasion in metastatic breast cancer Breast Cancer Res. Treat. 2012, 134 (2) 603-615
104. v1.8 in human prostate cancer is associated with high histological grade. J. Clin. Exp. Oncol. 2012, 1 (2), DOI: 10.4172/2324-9110.1000102.
105. v1.1 activators Trends Pharmacol. Sci. 2014, 35 (3) 113-118
106. v1.1 familial hemiplegic migraine mutant transformed into gain of function by partial rescue of folding defects Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (43) 17546-17551
107. v1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (20) 8520-8525
108. Waxman, S. G. Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status Nature Clin. Pract. Neurol. 2008, 4 (3) 159-169
109. Shields, S. D.; Cheng, X.; Gasser, A.; Saab, C. Y.; Tyrrell, L.; Eastman, E. M.; Iwata, M.; Zwinger, P. J.; Black, J. A.; Dib-Hajj, S. D.; Waxman, S. G. A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis Ann. Neurol. 2012, 71 (2) 186-194
110. For a recent review: Moczydlowski, E. G. The molecular mystique of tetrodotoxin Toxicon 2013, 63, 165-183
111. For a recent review: Thottumkara, A. P.; Parsons, W. H.; Du Bois, J. Saxitoxin Angew. Chem. Int. Ed. 2014, 53, 5760-5784
112. Chen, R.; Chung, S.-H. Mechanism of tetrodotoxin block and resistance in sodium channels Biochem. Biophys. Res. Commun. 2014, 446, 370-374
113. v1.6 voltage-dependent sodium channel Am. J. Physiol.: Cell Physiol. 2007, 293, C783-C789
114. Yotsu-Yamashita, M.; Kim, Y. H.; Dudley, S. C.; Choudhary, G.; Pfahnl, A.; Oshima, Y.; Daly, J. W. The structure of Zetekitoxin AB, a saxitoxin analog from the Panamanian golden frog Azelopus zeteki: a potent sodium channel blocker Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 4346-4351
115. Kudo, Y.; Finn, J.; Fukushima, K.; Sakugawa, S.; Cho, Y.; Konoki, K.; Yotsu-Yamashita, M. Isolation of 6-deoxytetrodotoxin from the pufferfish, Takfugu padalis, and a comparison of the effects of the C-6 and C-11 hydroxy groups of tetrodotoxin on its activity J. Nat. Prod. 2014, 77, 1000-1004
116. Satake, Y.; Adachi, M.; Tokoro, S.; Yotsu-Yamashita, M.; Isobe, M.; Nishikawa, T. Synthesis of 5- and 8-deoxytetrodotoxin Chem.-Asian J. 2014, 9 (7) 1922-1932
117. Dechraoui, M.-Y.; Naar, J.; Pauilac, S.; Legrand, A.-M. Toxicon 1999, 37 (1) 125-143
118. Rein, K. S.; Baden, D. G.; Gawley, R. E. Conformational analysis of the sodium channel modulator, brevetoxin A, comparison with brevetoxin B. Conformations, and a hypothesis about the common pharmacophore of the "site 5" toxins J. Org. Chem. 1994, 59, 2101-2106
119. v1.8-derived chimeric sodium channels expressed in HEK293 cells J. Biol. Chem. 2009, 284 (12) 7597-7605
120. Bottein Dechraoui, M.-Y.; Wacksman, J. J.; Ramsdell, J. S. Species selective resistance of cardiac muscle voltage gated sodium channels: characterization of brevetoxin and ciguatoxin binding sites in rat and fish Toxicon 2006, 48, 702-712
121. Zhang, X.; Cao, B.; Wang, J.; Liu, J.; Vian Tung, V. O.; Sing Lam, P. K.; Chan, L. L.; Li, Y. Neurotoxicity and reactive astrogliosis in the anterior cingulate cortex in acute ciguatera poisoning Neuromol. Med. 2013, 15, 310-323
122. Gingold, D. B.; Strickland, M. J.; Hess, J. J. Ciguatera fish poisoning and climate change: analysis of national poison center data in the united states 2001-2011 Environ. Health Perspect. 2014, 122 (6) 580-586
123. Wong, C.-K.; Hung, P.; Lo, J. Y. C. Ciguatera fish poisoning in Hong Kong-a 10 year perspective on the class of ciguatoxins Toxicon 2014, 86, 96-106
124. Tsumuraya, T.; Fujii, I.; Hirama, M. Preparation of anti-ciguatoxin monoclonal antibodies using synthetic haptens: sandwich ELISA detection of ciguatoxins J. AOAC Int. 2014, 97 (2) 373-379
125. Braidy, N.; Matin, A.; Rossi, F.; Chinain, M.; Laurent, D.; Guillemin, G. J. Neuroprotective effects of rosmarinic acid on ciguatoxin in primary human neurons Neurotox. Res. 2014, 25, 226-234
126. Daly, J. W.; Witkop, B.; Bommer, P.; Biemann, K. Batrachotoxin. The active principle of the Colombian arrow poison frog, Phyllobates bicolor J. Am. Chem. Soc. 1965, 87 (1) 124-126
127. Garraffo, H. M.; Spande, T. F. Discovery of batrachotoxin: the launch of the frog alkaloid program at NIH Heterocycles 2009, 79, 195-205
128. Mebs, D.; Alvarez, J. V.; Pogoda, W.; Toennes, S. W.; Kóhler, G. Poor alkaloid sequestration by arrow poison frogs of the genus Phyllobates from Costa Rica Toxicon 2014, 80, 73-77
129. Du Bois, J.; Devlin, A. S.; Logan, M. M.; Menard, F.; Toma, T. Batrachotoxin analogues, compositions, uses, and preparations thereof. U.S. Pat. Appl. Pub. US20140171410, June 19, 2014.
130. Ulbricht, W. Effects of veratridine on sodium currents and fluxes Rev. Physiol. Biochem. Pharmacol. 1998, 133, 1-54
131. Yoshinaka-Niitsu, A.; Yamagaki, T.; Harada, M.; Tachibana, K. Solution NMR analysis of the binding mechanism of DIVS6 model peptides of voltage-gated sodium channels and the lipid soluble alkaloid veratridine Bioorg. Med. Chem. 2012, 20, 2796-2802
132. Devane, W. A.; Hanus, L.; Breuer, A.; Pertwee, R. G.; Stevenson, L. A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 1992, 258, 1946-1949
133. Peng, L.; Khan, N.; Afaq, F.; Ye, C.; Mukhtar, H. In vitro and in vivo effects of water extract of white cocoa tea (Camellia ptilophylla) against human prostate cancer Pharm. Res. 2010, 27, 1128-1137
134. v1.8 in Xenopus oocytes Anesth. Analg. 2014, 118 (3) 554-562
135. Zhang, Y.; Jia, Y.-Y.; Guo, J.-L.; Liu, P.-Q.; Jiang, J.-M. Effects of (-)-gallocatechin-3-gallate on tetrodotoxin-resistant voltage-gated sodium channels in rat dorsal root ganglion neurons Int. J. Mol. Sci. 2013, 14, 9779-9789
136. Orjala, J.; Nagle, D. G.; Hsu, V. L.; Gerwick, W. H. Antillatoxin: an exceptionally ichthyotoxic cyclic lipopeptide from the tropical cyanobacterium Lyngbya majuscula J. Am. Chem. Soc. 1995, 117, 8281-8282
137. Berman, F. W.; Gerwick, W. H.; Murray, T. F. Antillatoxin and kalkitoxin, ichthyotoxins from the tropical cyanobacterium Lyngbya majuscula, induce distinct temporal paterns of NMDA receptor-mediated neurotoxicity Toxicon 1999, 37 (11) 1645-1648
138. Inoue, M. Chemical construction and structural permutation of neurotoxic natural product, antillatoxin: importance of the three-dimensional structure of the bulky side chain Proc. Jpn. Acad. (Ser. B) 2014, 90, 56-65
139. Lewis, R. J.; Dutertre, S.; Vetter, I.; Christie, M. J. Conus venom peptide pharmacology Pharmacol. Rev. 2012, 64 (2) 259-298
140. Gajewiak, J.; Azam, L.; Imperial, J.; Walewska, A.; Green, B. R.; Bandyopadhyay, P. K.; Raghuraman, S.; Ueberheide, B.; Bern, M.; Zhou, H. M.; Minassian, N. A.; Hagan, R.; Flinspach, M.; Liu, Y.; Bulaj, G.; Wickenden, A. D.; Olivera, B. M.; Yoshikami, D.; Zhang, M.-M. A disulfide tether stabilizes the block of sodium channels by the conotoxin μO§-GVIIJ Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (7) 2758-2763
141. vβ subunits alters the kinetics of inhibition of voltage-gated sodium channels by pore-blocking μ-conotoxins Br. J. Pharmacol. 2013, 168, 1597-1610
142. Cruz, L. J.; Gray, W. R.; Olivera, B. M.; Zeikus, R. D.; Kerr, L.; Yoshikami, D.; Moczydlowsky, E. Conus geograhphus toxins that discriminate between neuronal and muscle sodium channels J. Biol. Chem. 1985, 260, 9280-9288
143. Sato, K.; Yamaguchi, Y.; Ishida, Y. Roles of individual disulfide bridges in the conformation and activity of μ-conotoxin GIIIA, a peptide blocker of muscle sodium channels Int. J. Pept. Res. Ther. 2014, 20, 253-258
144. Zhang, M.-M.; Green, B. R.; Catlin, P.; Fiedler, B.; Azam, L.; Chadwick, A.; Terlau, H.; McArthur, J. R.; French, R. J.; Gulyas, J.; Rivier, J. E.; Smith, B. J.; Norton, R. S.; Olivera, B. M.; Yoshikami, D.; Bulaj, G. Structure/function characterization of μ-conotoxin KIIIA, an analgesic, nearly irreversible blocker of mammalian neuronal sodium channels J. Biol. Chem. 2007, 282 (42) 30699-30706
145. v1.1 through 1.8 identify those responsible for action potentials in sciatic nerve Proc. Natl. Acad. Sci. U. S. A. 2011, 108 (25) 10302-10307
146. Khoo, K. K.; Wilson, M. J.; Smith, B. J.; Zhang, M.-M.; Gulyas, J.; Yoshikami, D.; Rivier, J. E.; Bulaj, G.; Norton, R. S. Lactam-stabilized helical analogues of the analgesic μ-conotoxin KIIIA J. Med. Chem. 2011, 54, 7558-7566
147. Brady, R. M.; Zhang, M.-M.; Gable, R.; Norton, R. S.; Baell, J. B. De novo design and synthesis of a μ-conotoxin KIIIA peptidomimetic Bioorg. Med. Chem. Lett. 2013, 23, 4892-4895
148. Walewska, A.; Han, T. S.; Zhang, M.-M.; Yoshikami, D.; Bulaj, G.; Rolka, K. Expanding chemical diversity of conotoxins: peptoid-peptide chimeras of the sodium channel blocker μ-KIIIA and its selenopeptide analogues Eur. J. Med. Chem. 2013, 65, 144-150
149. Wang, C.-Z.; Zhang, H.; Jiang, H.; Lu, W.; Zhao, Z.-Q.; Chi, C.-W. A novel conotoxin from Conus striatus, μ-SIIIA, selectively blocking rat tetrodotoxin-resistant sodium channels Toxicon 2006, 47 (1) 122-132
150. Akondi, K. B.; Lewis, R. J.; Alewood, P. F. Re-engineering the μ-conotoxin SIIIA scaffold Biopolymers 2013, 101, 347-354
151. Shon, K. J.; Olivera, B. M.; Watkins, M.; Jacobsen, R. B.; Gray, W. R.; Floresca, C. Z.; Cruz, L. J.; Hillyard, D. R.; Brink, A.; Terlau, H.; Yoshikami, D. μ-Conotoxin PIIIA, a new peptide for discriminating among tetrodotoxin-sensitive Na channel subtypes J. Neurosci. 1998, 18 (12) 4473-4481
152. v1.4 PLoS One 2014, 9 (3) e93267
153. Zhang, M.-M.; Wilson, M. J.; Gajewjak, J.; Rivier, J. E.; Bulaj, G.; Olivera, B. M.; Yoshikami, D. Pharmacological fractionation of tetrodotoxin-sensitive sodium currents in rat dorsal root ganglion neurons by μ-conotoxins Br. J. Pharmacol. 2013, 169, 102-114
154. McIntosh, J. M.; Hasson, A.; Spira, M. E.; Gray, W. R.; Li, W.; Marsh, M.; Hillyard, D. R.; Olivera, B. M. A new family of conotoxins that blocks voltage-gated sodium channels J. Biol. Chem. 1995, 270 (28) 16796-16802
155. v1.8 by the analgesic gating modifier μO-conotoxin MrVIB J. Pharmacol. Exp. Ther. 2011, 338 (2) 687-693
156. Hillyard, D. R.; Olivera, B. M.; Woodward, S.; Corpuz, G. P.; Gray, W. R.; Ramilo, C.; Cruz, L. J. A molluscivorous conus toxin: conserved frameworks in conotoxins Biochemistry 1989, 28 (1) 358-361
157. + channels J. Biol. Chem. 2004, 279 (6) 4680-4685
158. Buczek, O.; Wei, D.; Babon, J.; Yang, X.; Fiedler, B.; Chen, P.; Yoshikami, D.; Olivera, B. M.; Bulaj, G.; Norton, R. S. Structure and sodium channel activity of an excitatory I1-superfamily conotoxin Biochemistry 2007, 46 (35) 9929-9940
159. v1.2, 1.6 and 1.7 Biochem. Pharmacol. 2008, 75, 2334-2344
160. + channel voltage sensor Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 15426-15431
161. Zhang, J. Z.; Yarov-Yarovoy, V.; Scheuer, T.; Karbat, I.; Cohen, L.; Gordon, D.; Gurevitz, M.; Catterall, W. A. Structure-function map of the receptor site for β-scorpion toxins in domain II of voltage-gated sodium channels J. Biol. Chem. 2011, 286 (38) 33641-33651
162. Durek, T.; Vetter, I.; Wang, C.-I.; Motin, L.; Knapp, O.; Adams, D. J.; Lewis, R. J.; Alewood, P. F. Chemical engineering and structural and pharmacological characterization of the α-scorpion toxin OD1 ACS Chem. Biol. 2013, 8, 1215-1222
163. Maertens, C.; Cuypers, E.; Amininasab, M.; Jalali, A.; Vatanpour, H.; Tytgat, J. Potent modulation of the voltage-gated sodium channel by OD1, a toxin from the scorpion Odonthobuthus doriae Mol. Pharmacol. 2006, 70 (1) 405-414
164. + channels Pain 2013, 154, 1204-1215
165. Li, T.; Xu, L.; Liu, H.; He, Y.; Liang, S.; Li, W.; Wu, Y. Characterization of a novel BmαTX47 toxin modulating sodium channels: the crucial role of expression vectors in toxin pharmacological activity Toxins 2014, 6, 816-829
166. Klint, J. K.; Senff, S.; Rupasinghe, D. B.; Er, S. Y.; Herzig, V.; Nicholson, G. M.; King, G. F. Spider-venom peptides that target voltage-gated sodium channels: pharmacological tools and potential therapeutic leads Toxicon 2012, 60, 478-491
167. Craik, D. J.; Daly, N. L.; Waine, C. The cysteine knot motif in toxins and implications for drug design Toxicon 2001, 39, 43-60
168. Shu, Q.; Liang, S. P. Purification and characterization of huwentoxin-II, a neurotoxic peptide from the venom of the Chinese bird spider Selenocosmia huwena J. Pept. Res. 1999, 53 (5) 486-491
169. Liu, Y.; Wu, Z.; Tang, D.; Xun, X.; Liu, L.; Li, X.; Nie, D.; Xiang, Y.; Yi, J.; Yi, J. Analgesic effects of Huwentoxin-IV on animal models of inflammatory and neuropathic pain Protein Pept. Lett. 2014, 21, 153-158
170. Deng, M.; Luo, X.; Jiang, L.; Chen, H.; Wang, J.; He, H.; Liang, S. Synthesis and biological characterization of synthetic analogs of huwentoxin-IV, a neuronal tetrodotoxin-sensitive sodium channel inhibitor Toxicon 2013, 71, 57-65
171. Park, J. H.; Carlin, K. P.; Wu, G.; Ilyin, V. I.; Musza, L. L.; Blake, P. R.; Kyle, D. J. Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage-gated sodium channels J. Med. Chem. 2014, 57 (15) 6623-6631
172. Smith, J. J.; Alphy, S.; Seibert, A. L.; Blumenthal, K. M. Differential phospholipid binding by site 3 and site 4 toxins J. Biol. Chem. 2005, 280 (12) 11127-11133
173. Liu, Z.; Dai, J.; Chen, Z.; Hu, W.; Xiao, Y.; Liang, S. Isolation and characterization of hainantoxin-IV, a novel antagonist of tetrodotoxin-sensitive sodium channels from the Chinese bird spider Selenocosmia hainana Cell. Mol. Life Sci. 2003, 60, 972-978
174. Cai, T.; Luo, J.; Meng, E.; Ding, J.; Liang, S.; Wang, S.; Liu, Z. Mapping the interaction site for the tarantula toxin hainantoxin-IV (β-TRTX-Hn2a) in the voltage sensor module of domain II of voltage-gated sodium channels. Peptides 2014, September 10.
175. Wang, H.; Zhang, F.; Li, D.; Xu, S.; He, J.; Yu, H.; Li, J.; Liu, Z.; Liang, S. The venom of the fishing spider Dolomedes sulfurous contains various neurotoxins acting on voltage-activated ion channels in rat dorsal root ganglion neurons Toxicon 2013, 65, 68-75
176. Kudo, Y.; Shibata, S. The potent excitatory effect of a novel polypeptide, anthopleurin-B, isolated from a sea anemone (Anthopleura xanthogrammica) on the frog spinal cord J. Pharmacol. Exp. Ther. 1980, 214 (2) 443-448
177. Moran, Y.; Gordon, D.; Gurevitz, M. Sea anemone toxins affecting voltage-gated sodium channels-molecular and evolutionary features Toxicon 2009, 54 (8) 1089-1101
178. Lazcano-Pérez, F.; Vivas, O.; Román-González; Rodríguez-Bustamante, E.; Castro, H.; Arenas, I.; García, D. E.; Sánchez-Puig, N.; Arreguín-Espinosa, R. A purified Palythoa venom fraction delays sodium current inactivation in sympathetic neurons Toxicon 2014, 82, 112-116
179. King, G. F. Venoms as a platform for human drugs: translating toxins into therapeutics Exp. Opin. Biol. Ther. 2011, 11 (11) 1469-1484
180. Zuliani, V.; Rapalli, A.; Patel, M. K.; Rivara, M. Sodium channel blockers: a patent review (2010-2014) Exp. Opin. Ther. Pat. 2015, 25 (3) 279-290
181. v1.7: patent applications since 2010 Pharm. Pat. Anal. 2014, 3 (5) 509-521
182. Markworth, C. J.; Marron, B. E.; Rawson, D. J.; Storer, R. I.; Swain, N. A.; West, C. W.; Zhou, S. Chemical compounds. PCT Int. Appl. WO2012004706, Mar 1, 2012.
183. A Clinical Trial To Evaluate PF-05089771 on Its Own and as an Add-on Therapy to Pregabalin (Lyrica) for the Treatment of Pain Due to Diabetic Peripheral Neuropathy (DPN). ClinicalTrials.gov; U.S. National Institutes of Health: Bethesda, MD, August 11, 2014; http://clinicaltrials.gov/ct2/show/NCT02215252?term=PF-05089771&rank=8 (accessed Mar 5, 2015).
184. Storer, R. I.; Swain, N. A. Sulfonamide derivatives and use thereof as VGSC inhibitors. PCT Int. Appl. WO2013093688, Jun 27, 2013.
185. Rawson, D. J.; Storer, R. I.; Swain, N. A. Sulfonamide derivatives. PCT Int. Appl. WO2013088315, Jun 20, 2013.
186. Brown, A. D.; Galan, S. R. G.; Millan, D. S.; Rawson, D. J.; Storer, R. I.; Stupple, P. A.; Swain, N. A. N-Aminosulfonyl benzamides. PCT Int. Appl. WO2013102826, Jul 11, 2013.
187. v1.8 channel modulators for the treatment of pain. PCT Int. Appl. WO2008135830, Nov 13, 2008.
188. Gibson, K. R.; Poinsard, C.; Glossop, M. S.; Kemp, M. I. Pyrazine derivatives. PCT Int. Appl. WO2007052123, Oct 5, 2007.
189. Bagal, S. K.; Brown, A. D.; Kemp, M. I.; Klute, W.; Marron, B. E.; Miller, D. C.; Skerrat, S. E.; Suto, M. J.; West, C. W.; Malet Sanz, L. Benzimidazole and imidazopyridine derivatives as sodium channel modulators. PCT Int. Appl. WO2013114250, Aug 8, 2013.
190. Convergence Pharmaceuticals Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy; Convergence Pharmaceuticals: Cambridge, UK, Sept 23, 2014; http://www.convergencepharma.com/userfiles/file/140923 LSRFINAL.pdf, (accessed Mar 20, 2015).
191. The Pipeline; Convergence Pharmaceuticals: Cambridge, UK, 2015; http://www.convergencepharma.com/?page
192. Giblin, G. M. P.; Witty, D. R.; MacPherson, D. T.; Stanway, S. J.; Wilson, A.; Gleave, L. Spiroderivatives as voltage-gated sodium channel modulators. PCT Int. Appl. WO2013179049, May 12, 2013.
193. Witty, D. R.; MacPherson, D. T.; Giblin, G. M. P.; Stanway, S. J. 2-(Pyridin-2yl)-1,7-diaza-spiro[4.4]nonane-6-one compound as voltage-gated sodium channels modulator. PCT Int. Appl. WO2013093496, Jun 27, 2013.
194. Witty, D. R.; MacPherson, D. T.; Giblin, G. M. P.; Stanway, S.; Vong, A. K. K. J. 2-(Pyridin-2yl)-1,7-diaza-spiro[4.4]nonane-6-one compounds as voltage-gated sodium channels modulators. PCT Int. Appl. WO2013093497, Jun 27, 2013.
195. Giblin, G. M. P.; MacPherson, D. T.; Witty, D. R.; Stanway, S. J. Novel compounds. PCT Int. Appl. WO2013175205, Nov 28, 2013.
196. Giblin, G. M. P.; MacPherson, D. T.; Witty, D. R.; Stanway, S. J. Novel compounds. PCT Int. Appl. WO2013175206, Nov 28, 2013.
197. Alvaro, G.; Large, C. Co-therapy for treatment of epilepsy and related disorders. PCT Int. Appl. WO2011015537, Feb 10, 2011.
198. Alvaro, G.; Andreotti, D.; Bergauer, M.; Giovannini, R.; Marasco, A. Prolinamide derivatives as sodium channel modulators. PCT Int. Appl. WO2007042250, Apr 19, 2007.
199. Bergauer, M.; Giovannini, R.; Profeta, R. Prolinamide derivatives as sodium channel modulators. PCT Int. Appl. WO2007042239, Apr 19, 2007.
200. Winters, C. S.; Yang, M.; Chen, H. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents. PCT Int. Appl. WO2011106729, Sep 1, 2011.
201. Sun, S.; Zenova, A. Y.; Chafeev, M.; Jia, Q.; Zhang, Z.; Oballa, R. M. Benzenesulfonamide compounds and their use as therapeutic agents. PCT Int. Appl. WO2013064983, Oct 5, 2013.
202. Liu, S.; Focken, T.; Chahal, N.; Zhang, Z.; Oballa, R. M.; Fonarev, J. Binary ether sulfonamides and their use as therapeutic agents. PCT Int. Appl. WO2013064984, Oct 5, 2013.
203. v1.7 Bioorg. Med. Chem. Lett. 2014, 24, 4397-4401
204. Andrez, J.-C.; Chowdhury, S.; Decker, S.; Dehnhardt, C. M.; Focken, T.; Grimwood, M. E.; Hemeon, I. W.; Jia, Q.; Li, J.; Ortwine, D. F.; Safina, B.; Sheng, T.; Sun, S.; Sutherlin, D. P.; Wilson, M. S.; Zenova, A. Y. N-substituted benzamides and their use in the treatment of pain. PCT Int. Appl. WO2013177224, Nov 28, 2013.
205. Dehnhardt, C. M.; Chowdhury, S.; Focken, T.; Grimwood, M. E.; Hemeon, I. W.; Safina, B.; Sutherlin, D. P. N-Substituted benzamides and methods use thereof. PCT Int. Appl. WO2014008458, Apr 17, 2014.
206. Selective Small-Molecule Sodium Channel Modulators for Dravet Syndrome, or DS; Xenon Pharmaceuticals, Inc.: Burnaby, BC, Canada, 2015; http://www.xenon-pharma.com/product-candidates/dravet-syndrome (accessed Mar 5, 2015).
207. Prospectus Summary: Xenon Pharmaceuticals Inc.; EDGAR Online, Inc.: New York, 2014; http://sec.edgar-online.com/xenon-pharmaceuticals-inc/s-1-securities-registration-statement/2014/09/10/section5.aspx (accessed Dec 15, 2015).
208. Tsuboi, K.; Yamai, Y.; Watanabe, H.; Kinoshita, H. Novel bicyclic heterocyclic compounds. PCT Int. Appl. WO2010074193, Jul 1, 2010.
209. Profile of Major Products under Development (as of January 29, 2015); Sumitomo Dainippon Pharma Co. Ltd.: Osaka, 2015; http://www.ds-pharma.com/rd/clinical/pipeline
210. ISRCTN Registry; BioMed Central Ltd: London, 2015; http://www.controlled-trials.com/ISRCTN80154838/DSP2230 (accessed Mar 5, 2015).
211. NKTR-171; Nektar: San Francisco, 2015; http://www.nektar.com/product pipeline/cnspainnktr-171.html (accessed Mar 5, 2015).
212. Riggs-Sauthier, J.; Deng, B.-L. Oligomer conjugates of lidocaine and its derivatives. PCT Int. Appl. WO2009054916, Apr 30, 2009.
213. TTX; WEX Pharmaceuticals, Inc.: Vancouver, BC, Canada, 2015; http://www.wextech.ca/clinical
214. Determine the Effect of AZD3161,Injected Intradermally, on Quantitative Sensory Testing Variables in Normal and Ultraviolet-C (UVC) Exposed Skin in Healthy Volunteers. ClinicalTrials.gov; U.S. National Institutes of Health: Bethesda, MD, Nov 10, 2010; http://clinicaltrials.gov/show/NCT01240148 (accessed Mar 5, 2015).
215. Boehm, J. C.; Davis, R. S.; Kerns, J.; Lin, G.; Murdoch, R. D.; Nie, H. Voltage-gated sodium channel blockers. PCT Int. Appl. WO2013006596, Jan 10, 2013.
216. GSK2339345 Hypertussive Challenge Study. ClinicalTrials.gov; U.S. National Institutes of Health: Bethesda, MD, July 11, 2013; https://clinicaltrials.gov/ct2/show/NCT01899768?term=GSK2339345&rank=3 (accessed Mar 5, 2015).
217. Kwong, K.; Webb, E. F.; Hunsberger, G. E.; Osborn, R. R.; Ghatta, S.; Ingleby, L.; Carr, M. J.; Kerns, J. K.; Rumsey, W. Pharmacological Characterization Of GSK2339345, A Novel Voltage-Gated Sodium Channel Blocker For The Symptomatic Relief Of Cough Am J. Resp. Crit. Care Med. 2013, 187, A4936 http://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2013.187.1
218. Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802. ClinicalTrials.gov; U.S. National Institutes of Health: Bethesda, MD, May 7, 2009; https://clinicaltrials.gov/ct2/show/NCT00908154?term=GSK1014802&rank=1 (accessed on Mar 5, 2015).
219. Corkey, B. K.; Elzein, E.; Jiang, R. H.; Kalla, R. V.; Kobayashi, T.; Koltun, D.; Li, X.; Martinez, R.; Notte, G.; Parkhill, E. Q.; Perry, T.; Zablocki, J.; Venkatara-Mani, C.; Graupe, M.; Guerrero, J. Fused heterocyclic compounds as sodium channel modulators. PCT Int. Appl. WO2012154760, Nov 15, 2012.
220. HIV/AIDS; Gilead: Foster City, CA, 2013; http://www.gilead.com/research/pipeline (accessed on Mar 5, 2015).
221. GS-6615. ClinicalTrials.gov; U.S. National Institutes of Health: Bethesda, MD, 2015; https://clinicaltrials.gov/ct2/results?term=GS6615&Search=Search; (accessed on Mar 5, 2015).
222. Gaskin, D. J.; Richard, P. The economic costs of pain in the United States J. Pain 2012, 13 (8) 715-724
223. Humble, S. R.; Dalton, A. J.; Li, L. A systematic review of therapeutic interventions to reduce acute and chronic post-surgical pain after amputation, thoracotomy or mastectomy Eur. J. Pain 2014, 19, 451-465 10.1002/ejp.567
224. Kroenke, K.; Krebs, E. E.; Bair, M. J. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews Gen. Hosp. Psychiatry 2009, 31, 206-219
225. Farre, C.; Fertig, N. New strategies in ion channel screening for drug discovery: are there ways to improve its productivity? Expert Opin. Drug Discovery 2014, 9 (10) 1103-1107
226. McCall, J.; M. Jacocks, H. M.; Niven, S. C.; Poli, M. A.; Baden, D. G.; Bourdelais, A. J. Development and utilization of a fluorescence-based receptor-binding assay for the site 5 voltgage-sensistive sodium channel ligands brevetoxin and ciguatoxin J. AOAC Int. 2014, 97 (2) 307-315